CDXC vs. INDV, AKRO, DYN, IMCR, EVO, GPCR, TVTX, VIR, SDGR, and XNCR
Should you be buying ChromaDex stock or one of its competitors? The main competitors of ChromaDex include Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Immunocore (IMCR), Evotec (EVO), Structure Therapeutics (GPCR), Travere Therapeutics (TVTX), Vir Biotechnology (VIR), Schrödinger (SDGR), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.
ChromaDex vs.
ChromaDex (NASDAQ:CDXC) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
ChromaDex received 537 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 64.50% of users gave ChromaDex an outperform vote.
ChromaDex has a net margin of 1.62% compared to Indivior's net margin of -0.17%. ChromaDex's return on equity of 4.85% beat Indivior's return on equity.
15.4% of ChromaDex shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 9.6% of ChromaDex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ChromaDex presently has a consensus target price of $8.00, indicating a potential upside of 34.68%. Indivior has a consensus target price of $16.00, indicating a potential upside of 37.34%. Given Indivior's higher probable upside, analysts plainly believe Indivior is more favorable than ChromaDex.
In the previous week, ChromaDex had 3 more articles in the media than Indivior. MarketBeat recorded 4 mentions for ChromaDex and 1 mentions for Indivior. Indivior's average media sentiment score of 0.43 beat ChromaDex's score of 0.26 indicating that Indivior is being referred to more favorably in the news media.
Indivior has higher revenue and earnings than ChromaDex. Indivior is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks.
ChromaDex has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
Summary
ChromaDex beats Indivior on 9 of the 16 factors compared between the two stocks.
Get ChromaDex News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ChromaDex Competitors List
Related Companies and Tools
This page (NASDAQ:CDXC) was last updated on 1/18/2025 by MarketBeat.com Staff
Free CDXC Stock Alerts